Please login to the form below
reimbursement models
This page shows the latest reimbursement models news and features for those working in and with pharma, biotech and healthcare.
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Shionogi strongly supports the
Latest news
-
Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany
With the rapid development of novel gene therapies also comes the need for new payment models that can accommodate the high cost of accessing these treatments. ... A report from The Alliance for Regenerative Medicine (ARM) published in July last year
-
The business case for patient engagement
b) Reimbursement models are evolving. Until recently, reimbursement was rather indirect, for example, by using digital medicines for safeguarding pay-for-performance deals and value-based reimbursement models. ... The next step is direct reimbursement of
-
UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
Our NHS is in a unique position to take a global lead in testing new payment models. ... The pilot scheme also reflects a new willingness and capability in the UK to try out new reimbursement models, primarily led by NHS England.
-
Europe urged to adapt faster to gene therapy challenges
Existing models include conditional reimbursement, such as England’s Cancer Drugs Fund and Scotland’s fund for ultra-orphan drugs. ... The report recommends a number of key measures, including:. A quick adoption of new payment models such as
-
Europe responding to gene therapy challenge, but picture remains fragmented
The Advanced Therapies &Regenerative Medicine congress, hosted by Terrapinn on Thursday, brought together a panel of experts who discussed emerging reimbursement and financing models in the US and Europe. ... However the changing dynamics of the pipeline
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Assessing the risks in annuity pricing models
Any of these issues can increase cost or risk. Adapting pricing and reimbursement models to accommodate these therapies could be a significant challenge, especially for higher-cost drugs or those involving ... Manufacturers will need to restructure
-
No incentive for a cure
Each of the different models are variations of a fee-for-service reimbursement model, which have evolved to meet the needs of chronic illnesses. ... Incremental changes may work in the short-term. Incremental changes include solutions such as
-
Lighting the way
This pathway would better align the current regulatory, reimbursement, evaluation and diffusion processes, and provide companies with tailored support in navigating the new, simplified system. ... reimbursement models” for greater patient access.
-
Market access improvements in Turkey
In 2015 there were 8, 104 products on the reimbursement list, with 292 new ones added. ... company. Alternative reimbursement models. The SGK was first authorised in September 2014 to develop 'alternative reimbursement models' as a new channel through
-
Managing real world data governance
These emerging regulatory and reimbursement models all aim to make treatment provision and access more sensitive to the evolving evidence base, and all require RWD. ... models. Where the appropriate safeguards are in place, authorisation should be based
More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Reflections of a Fireside Chat from the World Orphan Drug Congress 2020
As a business, Orchard Therapeutics want to introduce as many therapies as possible and, in order to enable a broader reach, are eager to work with regulators to explore reimbursement models
-
Innovation in pharma: the highs and lows of the current healthcare economy
The cycle of behavioural change. It’s already certain that more pragmatic reimbursement models will be required to deal with the cost of these new treatments as upfront payment will be
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
